This event brought together life science experts and entrepreneurs to explore what should be done to make the UK a scale-up market of choice. The event included a Keynote by George Freeman, MP and a panel discussion, moderated by Lord O’Shaughnessy. The event helped to raise awareness on what factors influence a companies’ decision on where to locate and what policies, investment and other changes can ensure the UK is as attractive and internationally competitive as possible.
News
- Bayland Capital and founding shareholder, CN Innovations Holdings Ltd, to invest $10M and $5.5M, respectively
- Investment will expand product development and scaling of the organization to meet increased demand for Organ-on-a-Chip (OOC) solutions
University of Oxford spin-out HydRegen has been revealed as the winner of a programme designed to recognise innovations in planetary health created by Pioneer Group in partnership with CPI.
Macomics Unveils its Lead First-in-Class Anti-Pan-LILRB Monoclonal Antibody Programme with Positive Pre-clinical Data Presented at AACR 2024
• Macomics’ lead programme, MACO-355, in IND enabling studies is a ligand-blocking independent pan-LILR monoclonal antibody for the treatment of cancer
• Data presented at AACR 2024 shows MACO-355 is highly potent in macrophage reprogramming under tumour-like immune suppressed conditions
• Data demonstrated Macomics’ ENIGMAC™ platform at-scale CRISPR screening for macrophage target discovery
Access to compound collection enables greater flexibility and efficiencies in screening and target identification
Cambridge, UK and Kyiv, Ukraine, 11th April 2024: Metrion Biosciences Limited (“Metrion”), the specialist ion channel and cardiac safety screening contract research organisation (CRO) and drug discovery company, and Enamine Ltd (“Enamine”), the global leader in supplying small molecules and early drug discovery services, announced that Metrion has enhanced its High Throughput Screening (HTS) services with the addition of access to Enamine’s compound libraries.
Read April's eNews
Growing Opportunities for our Network, featuring:
✅ Welcome from Tony Jones, CEO, One Nucleus
✅ Review of this year's BLSA (Building Life Science Adventures)
✅ Tony Jones reviews our Inaugural Annual Awards
✅ Boston Bootcamp Winners and What they Can Look Forward To
Regulatory Compliant Tissue Microarrays
AMSBIO reports that its extensive range of FDA tissue microarrays reliably enhances tissue cross-reactivity (TCR) and other target validation studies.
These high-quality tissue microarrays (TMAs) enable high-throughput analysis of a panel of tissue types recognized by the Food and Drug Administration (FDA) and the European Medicines Agency (EMA).
Astex Pharmaceuticals Announce Key Data Presentations at the American Association For Cancer Research (AACR) 2024 Annual Meeting
As technologies emerge that enable a wide range of naturally occurring medicinal compounds to be reproduced by a host plant within a controlled environment, is it time to review the use of plants as biofactories? Innovation facilitators Agri-TechE are partnering with the life-sciences network OneNucleus to explore the market potential of using plant factories to mass produce rare drugs. Find out more about the event here.
Laverock Therapeutics announces appointment of Ali Elsley as Finance Director and expansion of team
Stevenage, UK, 26 March 2024 - Laverock Therapeutics, a gene-silencing company with a uniquely powerful technology for the development of programmable advanced therapies to tackle major diseases, today announces the appointment of Ali Elsley as Finance Director.